| Ytd | 53.60% | |
| 1y | -56.73% |
| Open | 1.41 | Prev Close | 1.58 | Low | 1.38 | High | 1.80 | Mkt Cap | 48.92M |
| Vol | 1.87M | Avg Vol | 3.86M | EPS | -3.59 | P/E | N/A | Forward P/E | -4.00 |
| Beta | 0.54 | Short Ratio | 0.36 | Inst. Own | 14.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.77 | 200-d Avg | 1.13 | 1yr Est | 2.50 |
CELU News
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular
Celularity (CELU) stock surged 131% following a $300M U.S. manufacturing collaboration with MuseCell
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regul
Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualifi
[url="]Celularity Inc.[/url] (Nasdaq: CELU) (âCelularityâ), a longevity-focused regenerative and
The initial program is designed to establish manufacturing capability for MCI-authenticated DMC prep
FLORHAM PARK, N.J. & SINGAPORE--(BUSINESS WIRE)--Celularity Inc. and MuseCell Innovations announce U
Gainers Veeva Systems (NYSE:VEEV) shares increased by 8.7% to $266.15 during Wednesday's after-
Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market
FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”)
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-m
Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's
On June 29, 2026, Celularity Inc. (the "Company") entered into a Loan Agreement (the "L
FLORHAM PARK, N.J. and ORLANDO, Fla.
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" o
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” o
- Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellul
FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”),
Entry into a Material Definitive Agreement. As previously disclosed by Celularity Inc. (the "Com
Company advances focused strategy, strengthens balance sheet and positions business for long-term gr
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Busines
Transaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million an
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”)
Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular
FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”
Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both s
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is
FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”
Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and c
The transaction represents the most significant milestone in the company's history.
NexGel to acquire Celularity biomaterial products, a deal expected to triple revenue to $35 million
FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular
FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”),
Celularity Inc. Up to 14,078,938 shares of Class A Common Stock Pursuant to this prospectus, the sel
While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”),
FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”),
On December 1, 2025, Celularity Inc., (the "Company") received a warning letter (the "Le
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company a
Private Placement Transaction On October 24, 2025, Celularity Inc. (the "Company") entered i
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company a
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday'
WBB Securities analyst Steve Brozak upgrades Celularity (NASDAQ:CELU) from Hold to Buy and mainta
